Compare DHC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | MLYS |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2023 |
| Metric | DHC | MLYS |
|---|---|---|
| Price | $8.27 | $31.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.00 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $12.59 |
| 52 Week High | $9.14 | $47.65 |
| Indicator | DHC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 62.02 |
| Support Level | $6.92 | $30.96 |
| Resistance Level | $9.14 | $34.65 |
| Average True Range (ATR) | 0.30 | 1.46 |
| MACD | -0.06 | 0.34 |
| Stochastic Oscillator | 9.52 | 86.92 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.